<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00664209</url>
  </required_header>
  <id_info>
    <org_study_id>MJJF Clinical Discovery 2007</org_study_id>
    <secondary_id>441437-JB-58330</secondary_id>
    <nct_id>NCT00664209</nct_id>
  </id_info>
  <brief_title>Treating H. Pylori in Parkinson's Patients With Motor Fluctuations</brief_title>
  <official_title>Helicobacter Pylori Eradication and Motor Fluctuations in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Michael J. Fox Foundation for Parkinson's Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether treatment of H. pylori (an infection of the
      stomach) improves treatment effectiveness in patients with Parkinson's disease and motor
      fluctuations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous investigations have demonstrated that treatment of Helicobacter pylori with
      antibiotics leads to improved absorption and pharmacokinetics of levodopa. This may
      potentially benefit patients with Parkinson's disease who have motor fluctuations,
      specifically excessive &quot;off&quot; time, when their levodopa is not working to control symptoms. We
      seek to identify the frequency of H. pylori infection in this population using standard lab
      assays and determine whether eradication with standard triple therapy results in improved
      clinical response to medication.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Prevalence of H Pylori in the study population was much lower than anticipated
  </why_stopped>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>&quot;Off&quot; Time</measure>
    <time_frame>2 months</time_frame>
    <description>Average total daily &quot;off&quot; time (measured by patient symptom diaries) in hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in UPDRS Total Scores</measure>
    <time_frame>2 months</time_frame>
    <description>The Unified Parkinson Disease Rating Scale (UPDRS) is a rating tool to follow the longitudinal course of Parkinson's Disease. It is made up of the 1) Mentation, Behavior, and Mood, 2) ADL and 3) Motor sections. These are evaluated by interview. Some sections require multiple grades assigned to each extremity. A total of 199 points are possible. 199 represents the worst (total) disability), 0--no disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in UDPRS Part III</measure>
    <time_frame>2 months</time_frame>
    <description>Improvement in UDPRS Part III (Motor) scores (&quot;on&quot; and &quot;off&quot;) UPDRS III is the result of a motor examination with the scores 0-108. A decrease in the scores means improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Quality of Life as Assessed by PDQ-39</measure>
    <time_frame>2 months</time_frame>
    <description>The Parkinson's Disease Questionnaire (PDQ)-39 contains 39 questions addressing how often patients have experienced difficulties due to having PD in the preceding month. Items are scored from 0 (never) to 4 (always). Lower scores indicate better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Side Effects From Study Treatment</measure>
    <time_frame>2 months</time_frame>
    <description>Side effects profile</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Helicobacter Infections</condition>
  <condition>Motor Fluctuations</condition>
  <arm_group>
    <arm_group_label>Active-placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>These subject receive treatment with active triple therapy followed by treatment with placebo therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-active</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>These subject receive treatment with placebo therapy followed by treatment with active triple therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clartihromycin, amoxicillin, and omeprazole</intervention_name>
    <description>clarithromycin 500mg - i PO BID x10 days; amoxicillin 1gm - i PO BID x10 days; omeprazole 10mg - i PO BID x10 days</description>
    <arm_group_label>Active-placebo</arm_group_label>
    <arm_group_label>Placebo-active</arm_group_label>
    <other_name>Biaxin, Prilosec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo therapy</description>
    <arm_group_label>Active-placebo</arm_group_label>
    <arm_group_label>Placebo-active</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Adults diagnosed with idiopathic Parkinson's disease, Hoehn &amp; Yahr stage 2-4 in the
             &quot;off&quot; state, with no other concomitant neurologic diseases.

          -  Stable (≥30 days) Parkinson's disease therapy, with demonstrable medication efficacy,
             but with wearing off phenomenon present between levodopa doses (average off time ≥3
             hours off time/day).

          -  Levodopa therapy required; Any formulation (e.g. Sinemet, Sinemet CR, Stalevo) is
             acceptable. Parkinson's disease treatment may also include any of the following
             medications or classes: non-ergot dopamine agonists, COMT inhibitors, MAO-B
             inhibitors, amantadine, anticholinergics.

          -  Positive for H. pylori IgG Ab by serum ELISA (before inclusion in randomized treatment
             arms).

        Exclusion criteria:

          -  Current abdominal pain, unexplained nausea/vomiting, or gastrointestinal bleeding.

          -  History of gastric cancer, peptic ulcer, duodenal ulcer, or other gastric or duodenal
             lesions.

          -  History of previous gastric surgery.

          -  History of previous brain surgery for Parkinson's disease.

          -  Family history of gastric cancer.

          -  Prior treatment for H. pylori+ status.

          -  Recent use (previous 4 weeks) of proton-pump inhibitor, amoxicillin, or
             clarithromycin.

          -  Allergy or sensitivity to penicillin, amoxicillin, clarithromycin, or omeprazole.

          -  Use of drugs affecting gastric motility (e.g. domperidone, metoclopramide).

          -  Inability to tolerate or participate in testing in the morning in an &quot;off&quot; state.

          -  Inability to communicate effectively with study personnel in English.

          -  Pregnancy.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff M Bronstein, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA Neurology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Neurology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Belhoussine-Idrissi L, Boedeker EC. Helicobacter pylori infection: treatment. Curr Opin Gastroenterol. 2002 Jan;18(1):26-33.</citation>
    <PMID>17031226</PMID>
  </reference>
  <reference>
    <citation>Pierantozzi M, Pietroiusti A, Brusa L, Galati S, Stefani A, Lunardi G, Fedele E, Sancesario G, Bernardi G, Bergamaschi A, Magrini A, Stanzione P, Galante A. Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology. 2006 Jun 27;66(12):1824-9.</citation>
    <PMID>16801644</PMID>
  </reference>
  <reference>
    <citation>Pierantozzi M, Pietroiusti A, Galante A, Sancesario G, Lunardi G, Fedele E, Giacomini P, Stanzione P. Helicobacter pylori-induced reduction of acute levodopa absorption in Parkinson's disease patients. Ann Neurol. 2001 Nov;50(5):686-7.</citation>
    <PMID>11706979</PMID>
  </reference>
  <reference>
    <citation>Pierantozzi M, Pietroiusti A, Sancesario G, Lunardi G, Fedele E, Giacomini P, Frasca S, Galante A, Marciani MG, Stanzione P. Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson's disease patients. Neurol Sci. 2001 Feb;22(1):89-91.</citation>
    <PMID>11487216</PMID>
  </reference>
  <reference>
    <citation>Wolle K, Malfertheiner P. Treatment of Helicobacter pylori. Best Pract Res Clin Gastroenterol. 2007;21(2):315-24. Review.</citation>
    <PMID>17382279</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2008</study_first_submitted>
  <study_first_submitted_qc>April 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2008</study_first_posted>
  <results_first_submitted>October 31, 2017</results_first_submitted>
  <results_first_submitted_qc>October 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 2, 2017</results_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Jeff Bronstein</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>levodopa</keyword>
  <keyword>Helicobacter pylori</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of 64 enrolled, 13 positive for H. Pylori were screened for motor fluctuations (wearing off of the benefits of levodopa).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Active</title>
          <description>Those with significant wearing-off were to be assigned to arms, and received open-label triple eradication therapy (standard of care) per physician decision because the screen yield was too low to test effect size between arms.
---- Clarithromycin 500mg - i PO BID x10 days; Amoxicillin 1gm - i PO BID x10 days; Omeprazole 10mg - i PO BID x10 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Motor Fluctuations Screen</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Negative for motor fluctuation</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Study Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active</title>
          <description>H. Pylori positive participants screened for eligibility to a treatment assignment.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.4" lower_limit="51" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>&quot;Off&quot; Time</title>
        <description>Average total daily &quot;off&quot; time (measured by patient symptom diaries) in hours</description>
        <time_frame>2 months</time_frame>
        <population>Participants did not return symptom diaries</population>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>Standard treatment with active triple therapy</description>
          </group>
        </group_list>
        <measure>
          <title>&quot;Off&quot; Time</title>
          <description>Average total daily &quot;off&quot; time (measured by patient symptom diaries) in hours</description>
          <population>Participants did not return symptom diaries</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement in UPDRS Total Scores</title>
        <description>The Unified Parkinson Disease Rating Scale (UPDRS) is a rating tool to follow the longitudinal course of Parkinson's Disease. It is made up of the 1) Mentation, Behavior, and Mood, 2) ADL and 3) Motor sections. These are evaluated by interview. Some sections require multiple grades assigned to each extremity. A total of 199 points are possible. 199 represents the worst (total) disability), 0--no disability.</description>
        <time_frame>2 months</time_frame>
        <population>Subjects H pylori positive with greater than 4 hrs off time/day and completing the UDPRS</population>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>standard treatment with active triple therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in UPDRS Total Scores</title>
          <description>The Unified Parkinson Disease Rating Scale (UPDRS) is a rating tool to follow the longitudinal course of Parkinson's Disease. It is made up of the 1) Mentation, Behavior, and Mood, 2) ADL and 3) Motor sections. These are evaluated by interview. Some sections require multiple grades assigned to each extremity. A total of 199 points are possible. 199 represents the worst (total) disability), 0--no disability.</description>
          <population>Subjects H pylori positive with greater than 4 hrs off time/day and completing the UDPRS</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement in UDPRS Part III</title>
        <description>Improvement in UDPRS Part III (Motor) scores (&quot;on&quot; and &quot;off&quot;) UPDRS III is the result of a motor examination with the scores 0-108. A decrease in the scores means improvement</description>
        <time_frame>2 months</time_frame>
        <population>Subjects H pylori positive with greater than 4 hrs off time/day and completing the UDPRS</population>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>Standard treatment with active triple therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in UDPRS Part III</title>
          <description>Improvement in UDPRS Part III (Motor) scores (&quot;on&quot; and &quot;off&quot;) UPDRS III is the result of a motor examination with the scores 0-108. A decrease in the scores means improvement</description>
          <population>Subjects H pylori positive with greater than 4 hrs off time/day and completing the UDPRS</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement in Quality of Life as Assessed by PDQ-39</title>
        <description>The Parkinson's Disease Questionnaire (PDQ)-39 contains 39 questions addressing how often patients have experienced difficulties due to having PD in the preceding month. Items are scored from 0 (never) to 4 (always). Lower scores indicate better quality of life.</description>
        <time_frame>2 months</time_frame>
        <population>Subjects H pylori positive with greater than 4 hrs off time/day and completing the PDQ-29</population>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>Standard treatment with active triple therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in Quality of Life as Assessed by PDQ-39</title>
          <description>The Parkinson's Disease Questionnaire (PDQ)-39 contains 39 questions addressing how often patients have experienced difficulties due to having PD in the preceding month. Items are scored from 0 (never) to 4 (always). Lower scores indicate better quality of life.</description>
          <population>Subjects H pylori positive with greater than 4 hrs off time/day and completing the PDQ-29</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Side Effects From Study Treatment</title>
        <description>Side effects profile</description>
        <time_frame>2 months</time_frame>
        <population>All subjects receiving H. pylori treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>Standard treatment with active triple therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Side Effects From Study Treatment</title>
          <description>Side effects profile</description>
          <population>All subjects receiving H. pylori treatment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Active</title>
          <description>Standard treatment with active triple therapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Screening yield was much lower than anticipated based on the literature which prohibited completion of the study</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jeff Bronstein MD, PhD</name_or_title>
      <organization>UCaliforniaLA</organization>
      <phone>310 206-9799</phone>
      <email>jbronste@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

